Get the Stockscreener App
2.99
6.41%
0.18
After Hours:
3.05
0.06
+2.01%
Inozyme Pharma Inc stock is traded at $2.99, with a volume of 920.55K.
It is up +6.41% in the last 24 hours and up +7.17% over the past month.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
See More
Previous Close:
$2.81
Open:
$2.77
24h Volume:
920.55K
Relative Volume:
1.98
Market Cap:
$192.08M
Revenue:
-
Net Income/Loss:
$-71.17M
P/E Ratio:
-1.929
EPS:
-1.55
Net Cash Flow:
$-70.97M
1W Performance:
-1.32%
1M Performance:
+7.17%
6M Performance:
-32.05%
1Y Performance:
-23.72%
1-Day Range:
$2.75
$3.03
1-Week Range:
$2.65
$3.28
52-Week Range:
$2.385
$7.795
Inozyme Pharma Inc Stock (INZY) Company Profile
Name
Inozyme Pharma Inc
Sector
Industry
Phone
857-330-4340
Address
321 SUMMER STREET, BOSTON
Compare INZY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
2.99 | 192.08M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Raymond James | Outperform |
| Sep-12-24 | Initiated | Stifel | Buy |
| Aug-13-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| Mar-23-23 | Upgrade | Jefferies | Hold → Buy |
| May-26-22 | Initiated | Jefferies | Hold |
| Feb-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-29-21 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | BofA Securities | Buy |
| Aug-18-20 | Initiated | Cowen | Outperform |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Inozyme Pharma Inc Stock (INZY) Latest News
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of “Buy” by Analysts - Defense World
Inozyme Pharma (NASDAQ:INZY) Coverage Initiated at Raymond James - Defense World
Raymond James Begins Coverage on Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Jefferies initiates Buy rating on Inozyme Pharma stock, highlights potential of INZ-701 - Investing.com
Affinity Asset Advisors, LLC Increases Stake in Inozyme Pharma I - GuruFocus.com
Inozyme Pharma stock hits 52-week low at $2.53 amid market challenges - Investing.com Canada
Eventide Asset Management LLC Purchases 198,216 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Inozyme Pharma to Present at Piper Sandler Healthcare Conference | INZY Stock News - StockTitan
Inozyme Pharma stock hits 52-week low at $2.6 amid market challenges - Investing.com Canada
Analyzing Inozyme Pharma (NASDAQ:INZY) and Theratechnologies (NASDAQ:THTX) - Defense World
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
Inozyme Pharma Inc Stock (INZY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):